Generate a tailored SOP for Dr. Rita Nanda. Improve your application with a focused, well-structured draft.
Rita Nanda, MD, is an Associate Professor in the Department of Medicine at the University of Chicago, specializing in breast cancer. Her clinical interests include the efficacy of CDK4/6 inhibitors in early advanced hormone receptor-positive, HER2-negative breast cancer. Dr. Nanda has extensively contributed to research on treatment strategies and outcomes for breast cancer survivors, particularly focusing on treatment-related toxicity and mortality. Her noteworthy publications include studies on the comparative efficacy of sacituzumab govitecan versus physician's choice treatment methods in hormone receptor-positive breast cancer, and the impact of cyclin-dependent kinase inhibitors on patient health. She has also been involved in analyzing disparities in immunotherapy usage among patients with triple-negative breast cancer. Dr. Nanda's research includes exploring the characteristics of hormone receptor-positive HER2-negative breast cancers, revealing similarities to triple-negative breast cancers, and understanding the implications of glucocorticoid receptor expression on immune response in tumor environments. Her work aims to advance clinical practices in breast cancer treatment and improve patient outcomes.
Department of Philosophy